Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 26Gynecologic 9Tumor-Agnostic 6Lymphoid 5Genitourinary 5Sarcoma 4Other hematologic neoplasm 4Thoracic 3Endocrine 3Dermatologic 3Other solid neoplasm 2CNS 2Breast 2Head & Neck 1

Conditions

Lung Neoplasms 2Carcinoma 2Small Cell Lung Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Lung Diseases 1Disease 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × aflibercept × Thoracic × Clear all
NCT00532155 2025-09-10

VITAL

Sanofi

Phase 3 Completed
913 enrolled 16 charts
Thoracic

Carcinoma, Lung Neoplasms

NCT00828139 2017-08-21

S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
189 enrolled 15 charts
Thoracic

Small Cell Lung Carcinoma

NCT00284141 2012-12-10

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

Sanofi

Phase 2 Completed
98 enrolled 14 charts
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Disease, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡